SBIR Phase I: Multiwavelength Laser Spectroscopy System for Non-Invasive Bio-Assay

这一小型企业创新研究第一阶段研究项目将展示用于便携式和可穿戴的近红外、多波长光谱分析装置的光源的可行性。这将使便携式、非侵入性血液光谱学成为可能，用紧凑、高效的半导体激光器光源取代基于钨丝的光源。将展示一种激光技术平台，该平台可以具有成本效益的方式扩展，以访问临床相关的1350 nm至2450 nm波长范围，其中包括用于检测血液乙醇、尿素或葡萄糖的最佳指纹范围。这将导致一个强大而高效的光源/光谱平台，使基于光学的非侵入性人体健康监测系统的性能显著提高和尺寸缩小。该项目的商业应用将在糖尿病的管理和治疗中实现。糖尿病是一种影响数百万美国人的疾病。众所周知，这种疾病造成的慢性损害很大程度上是由于长期对血糖水平监测不足造成的。一个强大的实时监测和干预血糖水平变化的战略将对这数百万人以及全球数百万人的生活质量产生革命性的影响。

This Small Business Innovation Research Phase I research project will demonstrate the feasibility of a light source for a portable and wearable near infrared, multi-wavelength spectroscopy unit. This will enable portable, non-invasive blood spectroscopy by the displacement of tungsten filament based light sources with compact, efficient light sources based on semiconductor lasers. A laser technology platform that is scalable in a cost effective manner to access the clinically relevant 1350nm to 2450nm wavelength range, which includes an optimal fingerprint range for the sensing of blood ethanol, urea or glucose, will be demonstrated. This will result in a robust and efficient light source / spectroscopy platform that will enable dramatic performance improvements and size reductions in systems for optically based non-invasive monitoring of human health.The commercial application of this project will in the management and treatment of diabetes. Diabetes is a disease that affects millions of Americans. It is well known that much of the chronic damage from this disease results from inadequate monitoring of blood sugar levels over time. A robust strategy for real time monitoring and intervention in glucose level variation will have a revolutionary impact on the quality of life for these millions, and millions more worldwide.